Why Treatment Advances in Fibromyalgia Have Been Slow

Fibromyalgia is a common medical condition characterized by chronic widespread muscle pain, fatigue, and sleep disturbance affecting two to three percent of the total population. It is five to ten times more common in women than men, increases with age and can also be worsened by many factors, including physical trauma and emotional stress. In…

Read more on Why Treatment Advances in Fibromyalgia Have Been Slow

505(b)(2) New Drug Applications: Is there an adequate ROI?

In this post, intended for a general audience, I share a few thoughts about the benefits and limitations of developing drugs using the 505(b)(2) regulatory pathway. Hardly a week goes by without a pharmaceutical company expressing the desire to reap the benefits of developing a drug using the “505(b)(2) regulatory pathway”. What are 505(b)(2) new drug…

Read more on 505(b)(2) New Drug Applications: Is there an adequate ROI?

Najib Babul – Opioids for Neuropathic Pain: Worth the Risk?

Published on December 29, 2016 by Dr. Najib Babul Neuropathic pain is pain arising as a direct consequence of a lesion or disease affecting the somatosensory system, or put more simply, pain due to injury to sensory nerves. Neuropathic pain can be broadly divided into peripheral neuropathic pain and central neuropathic pain. Until relatively recently,…

Read more on Najib Babul – Opioids for Neuropathic Pain: Worth the Risk?